慢性阻塞性肺病急性发作期应用沐舒坦雾化吸入治疗的疗效观察

目的探讨沐舒坦雾化吸入治疗慢性阻塞性肺病急性发作期的临床疗效观察。方法将90例患者随机分为观察组和对照组(各45例),观察组在常规治疗的基础上给予沐舒坦雾化吸入治疗,对照组在常规治疗的基础上给予庆大霉素和α-糜蛋白酶雾化吸入治疗。结果观察组总有效率为95.6%,明显优于对照组的73.3%,两组总有效率比较差异具有统计学意义(P<0.05)。结论应用沐舒坦雾化吸入治疗慢性阻塞性肺病急性发作期疗效显著,能够有效改善患者临床症状,不良反应少,值得临床推广。

Efficacy of Chronic Obstructive Pulmonary Disease with Acute Exacerbation of Application Ambroxol Inhalation Therapy

Objective Explore mucosolvan inhalation treatment of chronic obstructive pulmonary disease with acute exacerbation of clinical observation. Methods 90 patients were randomly divided into observation group and control group （45 cases）, the observation group on the basis of conventional therapy give mucosolvan inhalation therapy, the control group was given on the basis of conventional therapy of gentamicin and alpha-the chymotrypsin inhalation treatment. Results The total effective rate was 95.6%, significantly better than the 73.3% of the control group, the total effective rate difference was statistically significant （P〈0.05）. Conclusion The application mucosolvan inhalation treatment of chronic obstructive pulmonary disease with acute exacerbation of a significant effect, can effectively improve the clinical symptoms, adverse reactions, is worthy of clinical expansion.